Drugs / Mescaline sodium enteric-coated tablets
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05933213 | Jul 2023 → Jul 2025 | lupus nephritis | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mescaline sodium enteric-coated tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05933213 ↗ |
| Route | Oral | “Induction period: orally, twice a day, at 720-1440 mg/d； Maintenance period: orally, twice a day, 360-540mg/d” NCT05933213 ↗ |